Anna Sanchez, DPM
Podiatrist · San Antonio, TXNPI 1881780468
Payments from drug & device makers
What this record shows
This record is dominated by gifts: $65,000 of the $71,856 with a category attached, or 90.5%. Smith+Nephew accounts for 91.6% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2020 at $65,210 and has fallen 99.8% since, to $104 in 2025. Among podiatrist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $378.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$66K
- Convatec Inc.$3K
- Melinta Therapeutics, LLC$729
- Paratek Pharmaceuticals, Inc.$608
- Organogenesis Inc.$272
- Amgen$256
- plus $1K from 20 others
Across 54 payments — averaging $2724.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Organogenesis Inc.$46K
- Endo Pharmaceuticals Inc.$36K
- Biotissue Holdings Inc.$36K
- Ipsen Innovation$24K
- Globus Medical$5K
What the payments were for
- Food & beverage$4,0556%
- Education$10%
- Gifts$65,00090%
- Other$2,8004%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 56 | $65,852 |
| Convatec Inc. | 1 | $2,800 |
| Melinta Therapeutics, LLC | 43 | $729 |
| Paratek Pharmaceuticals, Inc. | 26 | $608 |
| Organogenesis Inc. | 10 | $272 |
| Amgen | 6 | $256 |
| Biotissue Holdings Inc. | 3 | $253 |
| Imbed Biosciences Inc. | 11 | $159 |
| Sebela Pharmaceuticals Inc. | 5 | $116 |
| AbbVie(2 entities) | 5 | $97 |
| Medline Industries LP | 2 | $92 |
| Triad Life Sciences Inc. | 3 | $90 |
| Polarityte, Inc. | 1 | $86 |
| Integra Lifesciences Corporation | 3 | $72 |
| Abbott | 1 | $67 |
| Kerecis Limited | 1 | $64 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $51 |
| Vaporox, Inc. | 1 | $37 |
| GRT US Holding, Inc. | 3 | $35 |
| Tactile Systems Technology Inc | 2 | $26 |
| Mimedx Group, Inc. | 1 | $26 |
| Medela LLC | 1 | $16 |
| Glenmark Therapeutics Inc. | 1 | $15 |
| Merck | 1 | $13 |
| Nabriva Therapeutics, PLC | 1 | $12 |
| Bioventus LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GRAFIX PL$65,000
- Grafix$65,000
- InnovaMatrix AC$2,800
- NUZYRA$360
- KRYSTEXXA$193
- Kimyrsa$118
- COLLAGENASE SANTYL$114
- PuraPly$110
How this compares
$71,856 in reported general payments places this provider in the 95th percentile of 470 podiatrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 40 | $26,288 |
| RegranexBecaplermin | 12 | $25,208 |
| Linezolid | 25 | $1,648 |
| Ketoconazole | 66 | $909 |
| Mupirocin | 90 | $894 |
| Ciprofloxacin Hcl | 34 | $350 |
| Naltrexone Hcl | 12 | $343 |
| Moxifloxacin Hcl | 11 | $329 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $93 |
| Levofloxacin | 13 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl, Regranex | $65,852 | $51,49652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 470 podiatrist providers in Texas.
Other podiatrist in San Antonio
- Lee RogersSan Antonio$65K
- Boyd BillsSan Antonio$12K
- Brian CarpenterFort Worth$1.2M
- Gary LepowHouston$1M
- Wayne HurstCedar Park$625K
- Calvin RushingSunnyvale$452K
- Alan GarrettFort Worth$185K
- Gregory JarygaFt Worth$175K
- Brandon LampeMesquite$154K
- Andrew SchneiderHouston$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.